Scienion AG has closed a financing round totaling more than 4.5 million Euro. The cash inflow enables the development of new technologies and thus the further expansion of the company. In order to develop these new technologies Scienion will establish a second development and production site in Dortmund and will move into new facilities in the BioMedizinZentrum Dortmund.
Berlin, Germany, July 18, 2006: The investment was led by the new investors NRW.BANK and S-Venture Capital Dortmund GmbH and current VC investor Peppermint. Financial Partners. The VC Fonds Berlin of IBB Beteiligungsgesellschaft and ERP Start Fonds of Kreditanstalt für Wiederaufbau (KfW) participated in this round together with other existing Scienion investors. Dr. Holger Eickhoff, CEO of Scienion, explains: "We will use the new capital for developing innovative technologies in the field of low level liquid handling and its various applications as we face growing needs in this market. The BioMedizinZentrum Dortmund offers attractive conditions for our expansion and that’s why we build up a second development and production site here."
"We invest in Scienion because of its convincing business plan, and we are glad to get this innovative company to Nordrhein-Westfalen," says Ernst Gerlach, CEO of NRW.BANK. Dr. Joachim Rautter of Peppermint. Financial Partners adds: "Since our investment in 2001 we have accompanied Scienion’s successful development and with this new round we want to accelerate this positive development. Scienion has products and plans with a high market potential in the life science sector and that is the reason why we further invest in the company."
In its first financing round in 2001, Scienion raised start financing of approximately 6 million Euro. From the beginning of operations, Scienion has generated revenues with its innovative products and services that continually show high rates of growth.
SCIENION AG is a Berlin-based life science company offering complete solutions in the field of parallel bioanalytics. Customers include pharma and biotech companies as well as academic research institutions. Founded in December 2000 as a spin-off of the Max-Planck-Institute for Molecular Genetics, the company was originally focused on biochip platform technologies. With the successful launch of the sciFLEXARRAYER dispensing system in 2003, the company´s focus has been switched to hardware.
The sciFLEXARRAYER allows the aspiration of ultra low level liquid volumes from different reservoirs and contact-free micro drop delivery in the picoliter range onto a variety of carriers. Today, Scienion represents a rapidly growing company, well positioned in the field of ultra low level liquid handling systems including applications in genomics, proteomics and high throughput.
Dr. Holger Eickhoff, CEO
Tel.: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701
Email: firstname.lastname@example.org Pressekontakt
Tel. + 49 (0)30 – 6120 1081